New Haven, Conn. — A specially engineered antibody capable of delivering RNA therapies to hard-to-reach, treatment-resistant tumors significantly shrank tumor size and improved survival in animal models, according to a study published July 16 in Science Translational Medicine. The study provides evidence that, once injected into the bloodstream, the antibody TMAB3, combined with a type of RNA that stimulates an innate immune reaction, can localize to tumors and penetrate and destroy stubborn diseased cells in pancreatic, brain, and skin cancers. The research reported in this news article was supported by the National Institutes of Health (awards R35CA197574, K99-R00 CA226342 (LFE-H), R01CA274355, DP2CA280625, R01CA149128, T32GM007205); the Damon Runyon Cancer Research Foundation; the American Association for Cancer Research; Pew Cancer Research Scholars; Cancer Research Institute-Clinic & Laboratory Integration Program (CLIP); Yale Cancer Center; Blavatnik Fund for Innovation at Yale; Gennao Bio Sponsored Research Grant to Yale; and Yale University.
Yale Researchers Develop Novel Antibody-RNA Therapy for Resistant Cancers
Learn More
Discover the cutting-edge science we fund
Providing many of the world's best researchers, scientists, and universities with support, and funding to discover breakthroughs that solve humankind's greatest challenges.
See how we support great cultural institutions around the world
The Foundation contributes to renowned institutions that showcase the breadth of arts and culture, including performance, exhibition and education.
Visit the Blavatnik Archive
The Blavatnik Archive is a nonprofit foundation dedicated to preserving and disseminating materials that contribute to the study of 20th-century Jewish and world history, with a special emphasis on World War I, World War II, and Soviet Russia.